微信关注
China
Total item
Cart Subtotal
￥ 0.00 Angiogenesis
Angiogenesis is the formation and remodelling of new blood vessels and capillaries from growth of pre-existing blood vessels. It normally occurs during wound healing and embryonic development, but is also required for tumour growth and metastasis in cancer.
-
PF-4618433
Catalog No. A13461 -
NVP-TAE 226
Catalog No. A11507 FAK 抑制剂NVP-TAE 226是一种强效FAK抑制剂，IC50为5.5 nM，对pyk2(IC50=3.5 nM)有适度的强效作用；对InsR, IGF-1R, ALK和c-Met的效力降低10-100倍。 了解更多 -
GSK2256098
Catalog No. A15765 -
PROTAC FAK degrader 1
Catalog No. A18946 FAK degraderPROTAC FAK degrader 1 is a selective and potent focal adhesion kinase (Fak) degrader with an IC50 of 6.5 nM, DC50 of 3 nM. 了解更多 -
Defactinib
Catalog No. A21958 FAK inhibitorDefactinib (VS-6063; PF-04554878) is a novel FAK inhibitor with potential antiangiogenic and antineoplastic activities. 了解更多 -
Defactinib hydrochloride
Catalog No. A22003 FAK inhibitorDefactinib hydrochloride (VS-6063 hydrochloride; PF 04554878 hydrochloride) is a novel FAK inhibitor, which inhibits FAK phosphorylation at the Tyr397 site in a time- and dose-dependent manner. 了解更多 -
PF-04554878 (Defactinib)
Catalog No. A11929 FAK 抑制剂PF-04554878 (Defactinib)是一种新型FAK激酶抑制剂，可降低胰腺神经内分泌肿瘤细胞的生长并诱导其凋亡。 了解更多 -
PCI-32765 (Ibrutinib)
Catalog No. A11020 Bruton tyrosine kinase 抑制剂PCI-32765 (Ibrutinib)是Bruton酪氨酸激酶（BTK）的口服生物利用小分子抑制剂，具有潜在的抗肿瘤活性。对Bmx，CSK，FGR，BRK及HCK适度有效，对EGFR，Yes，ErbB2，JAK3等作用效果较弱。 了解更多 -
CGI1746
Catalog No. A11348 -
GDC-0834 Racemate
Catalog No. A12706 -
AVL-292 benzenesulfonate
Catalog No. A15008 BTK 抑制剂AVL-292 benzenesulfonate是一种共价，高选择性，口服活性的Btk小分子抑制剂，IC50值为0.5 nM，选择性是其他测定激酶的1400倍以上。 了解更多 -
ACP-196 (Acalabrutinib)
Catalog No. A15824 Btk 抑制剂ACP-196是Bruton酪氨酸激酶（BTK）抑制剂，具有潜在的抗肿瘤活性。它抑制BTK的活性并阻止B细胞抗原受体（BCR）信号传导途径的激活。 了解更多 -
BMS-935177
Catalog No. A16905 -
Vecabrutinib
Catalog No. A17189 -
PF-06250112
Catalog No. A18612 BTK 抑制剂PF-06250112 is a potent, highly selective, orally bioavailable BTK inhibitor with an IC50 of 0.5 nM, shows inhibitory effect toward BMX nonreceptor tyrosine kinase and TEC with IC50s of 0.9 nM and 1.2 nM, respectively. 了解更多 -
Olmutinib (HM61713)
Catalog No. A15976 -
Btk inhibitor 1
Catalog No. A16260 -
LFM-A13
Catalog No. A16261 -
PCI 29732
Catalog No. A16262 -
Poseltinib (HM71224, LY3337641)
Catalog No. A19450 BTK inhibitorPoseltinib, an orally active, selective and irreversible Bruton??s tyrosine kinase (BTK) inhibitor (IC50 =1.95 nM), with 0.3, 2.3 and 2.4-fold selectivity for BTK over BMX, TEC and TXK, respectively. 了解更多 -
CHMFL-BTK-01
Catalog No. A12538 BTK inhibitorCHMFL-BTK-01 (compound 9) is a highly selective irreversible BTK inhibitor, with an IC50 of 7 nM. CHMFL-BTK-01 (compound 9) potently inhibited BTK Y223 auto-phosphorylation. 了解更多 -
Ibrutinib Racemate
Catalog No. A18022 Btk inhibitorIbrutinib Racemate (PCI-32765 Racemate) is the racemate of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with IC50 value of 0.5 nM. 了解更多 -
(R)-Zanubrutinib
Catalog No. A21342 BTK inhibitor(R)-Zanubrutinib is the R enantiomer of Zanubrutinib. Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor. 了解更多 -
Btk inhibitor 1 (R enantiomer)
Catalog No. A21861 BTK inhibitorBtk inhibitor 1 R enantiomer (Ibrutinib analog) (Compound 14) is a covalent and irreversible Bruton??s tyrosine kinase (BTK) inhibitor and can be used in synthesis of Ibrutinib and ibrutinib-based activity-based probes (ABPs). 了解更多 -
Btk inhibitor 1 R enantiomer hydrochloride
Catalog No. A21865 BTK inhibitorBtk inhibitor 1 R enantiomer hydrochloride (Ibrutinib analog hydrochloride) (Compound 14) is a covalent and irreversible Bruton??s tyrosine kinase (BTK) inhibitor and can be used in synthesis of Ibrutinib and ibrutinib-based activity-based probes (ABPs). 了解更多 -
GDC-0834
Catalog No. A21243 -
Tirabrutinib
Catalog No. A21019 BTK inhibitorTirabrutinib (ONO-4059) is a highly selective, orally bioavailable BTK inhibitor with an IC50 of 2.2 nM. 了解更多 -
ASP3026
Catalog No. A11773 -
ALK-IN-1 (Brigatinib analog, AP26113 analog)
Catalog No. A11948 ALK 抑制剂AP26113是一种有效的，选择性的ALK抑制剂，对野生型的功效为0.62 nM，对包括crizotinib耐药的L1196M系在内的多种突变体的活性也很强。在一组EML4-ALK或NPM-ALK阳性细胞系中，AP26113的IC50值为4-31 nM。 了解更多 -
CEP-28122
Catalog No. A13744
FILTER BY:
购物选项
- 分类
- 作用机制
-
- Inhibitor (抑制剂) (403)
- Antagonist (拮抗剂) (2)
- Activator (激活剂) (3)
- Degrader (降解剂) (3)
- 靶点
-
- Abl (6)
- ALK (1)
- Aurora A (8)
- Aurora B (4)
- Aurora C (1)
- Axl (1)
- B-Raf (3)
- Bcr-Abl (1)
- C-Raf (Raf-1) (3)
- CDK (2)
- CDK2 (2)
- CDK4 (1)
- Chk2 (1)
- CSF1R (5)
- DNMT (1)
- EGFR (23)
- EGFR Exon 19 Deletion (1)
- EGFR L858R (5)
- EGFR L861Q (2)
- EGFR T790M (9)
- EGFR wild type (2)
- EphB4 (2)
- ErbB2 (3)
- ErbB3 (1)
- ErbB4 (2)
- FAK (10)
- FGFR (2)
- FGFR1 (23)
- FGFR2 (11)
- FGFR3 (12)
- FGFR4 (9)
- FLT3 (28)
- HDAC (1)
- HER2 (2)
- IGF1R (1)
- JAK1 (1)
- JAK2 (9)
- JAK3 (3)
- Kit (14)
- Lck (1)
- Lyn (1)
- Mer (1)
- PDGFR (1)
- PDGFRα (10)
- PDGFRβ (18)
- PKCα (1)
- PKCβ (1)
- PYK2 (4)
- RET (6)
- Src (5)
- STAT1 (1)
- Syk (2)
- TrkA (2)
- VEGFR1 (FLT1) (12)
- VEGFR2 (FLK1) (25)
- VEGFR3 (FLT4) (11)
联系我们
United StatesAdooq Bioscience
Toll Free: (866) 930-6790
Fax: +1-323-606-8156
Email: sales@adooq.com
Not your Region? View all Distributors
ADOOQ 产品质量保证
We promise all products to perform as described.